期刊
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
卷 25, 期 3, 页码 269-271出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/cap.2014.0119
关键词
-
资金
- Asahi Kasei Pharma
- Astellas Pharma
- Daiichi Sankyo
- Dainippon Sumitomo Pharma
- Eisai
- Eli Lilly Japan
- GlaxoSmithKline
- Janssen Pharmaceutical
- Meiji Seika Pharma
- Mitsubishi Tanabe Pharma
- Mochida Pharmaceutical
- MSD
- Otsuka Pharmaceutical
- Pfizer Japan
- Shionogi
- Tsumura
- Yoshitomiyakuhin
- Mitsubishi Tanabe Pharma Corporation
Objective: Recent studies suggest that the severity and drug response of depression and anxiety are correlated with childhood abuse. However, whether a history of child abuse can predict the severity and/or drug response of attention-deficit/hyperactivity disorder (ADHD) is unclear. Therefore, we conducted a retrospective study to assess the efficacy of atomoxetine in children with a history of child abuse. Methods: We reviewed 41 cases of children treated with atomoxetine. Specifically, we compared dissociation associating symptoms (DAS) and other symptoms (OS) measured via the ADHD Rating Scale (ADHD-RS) in abused and nonabused children at baseline and at 8 weeks after atomoxetine administration. Results: At baseline, abused children had higher total scores (38.7 +/- 9.3 vs. 30.5 +/- 9.4, p=0.011), and greater levels of hyperactivity/impulsivity (17.3 +/- 5.8 vs. 11.3 +/- 6.0, p=0.004) on the ADHD-RS than did nonabused children, whereas the inattention scores were similar between the two groups (21.4 +/- 4.8 vs. 19.2 +/- 4.6). Additionally, the total score and the two subscores decreased at week 8 for both groups. In the nonabused group, DAS (5.5 +/- 2.3 vs. 3.9 +/- 1.7, p<0.001) and OS (25.0 +/- 8.1 vs. 17.4 +/- 6.7, p<0.001) significantly decreased after atomoxetine treatment. However, DAS in the abused group did not change after atomoxetine treatment (5.9 +/- 2.3 vs. 5.1 +/- 1.8), whereas OS significantly decreased (32.8 +/- 7.6 vs. 25.7 +/- 7.2, p=0.002). Conclusions: If DAS were caused by traumatic experiences in abused children, trauma treatment tools other than pharmacotherapy might be useful to treat DAS. These tools may include eye movement desensitization and reprocessing and trauma-focused cognitive behavioral therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据